financetom
Business
financetom
/
Business
/
Update: Foran Mining Provides Construction Update for McIlvenna Bay Project in Saskatchewan
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Foran Mining Provides Construction Update for McIlvenna Bay Project in Saskatchewan
Dec 3, 2024 8:37 AM

11:22 AM EST, 12/03/2024 (MT Newswires) -- (Adds analyst comment.)

Foran Mining (FOM.TO) said Tuesday it continues to advance the construction of the McIlvenna Bay copper-zinc-gold-silver project in Saskatchewan.

The company outlined the progress of work at the project, including the rebar installation for the process plant building, installation of the semi-autogenous grinding mill shell, completion of under-pad earthworks for the waste rock and ore pad expansion, and continued aggregate material crushing operations.

A 2022 feasibility study on McIlvenna Bay outlined reserves of that would potentially support an 18-year mine life, producing an average of 65-million pounds of copper equivalent annually.

National Bank of Canada reiterated its outperform, speculative-risk, rating and $5.75 price target on Foran's shares following the release.

The bank said its rating recognizes its thesis is contingent on Foran's execution and future growth, net government tax credits and significant exploration.

"Foran tends to trade at a premium versus developer peers (0.64x NAVPS average) due to its near-term development and Tier 1 jurisdiction and supportive backers," National Bank said.

Foran shares were last seen up $0.06 to $4.12 on the Toronto Stock Exchange.

Price: 4.12, Change: +0.06, Percent Change: +1.48

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
EU antitrust regulators escalate Visa, Mastercard probe, documents show
EU antitrust regulators escalate Visa, Mastercard probe, documents show
Jun 3, 2025
BRUSSELS (Reuters) -EU antitrust regulators are asking retailers and payments companies whether a standardized summary of fees by Visa and Mastercard ( MA ) and more transparency on the charges would address their concerns, according to documents seen by Reuters. The latest questionnaires sent on Tuesday, which came nearly two months after the last batch, suggest that EU regulators have...
Colabor Group Up 2.5% As Completes Acquisition of Certain Alimplus Assets for $49.75 Million
Colabor Group Up 2.5% As Completes Acquisition of Certain Alimplus Assets for $49.75 Million
Jun 3, 2025
03:33 PM EDT, 06/03/2025 (MT Newswires) -- Colabor Group ( COLFF ) was at last look up 2.5% late Tuesday afternoon as ait closed the acquisition of certain assets from Alimplus, a Quebec-based private food distributor. The acquisition involves the food distribution assets of Alimplus, operating under the name Mayrand Plus, and all of the issued and outstanding shares of...
Immix Biopharma's NXC-201 Trial Meets Primary Endpoint in AL Amyloidosis
Immix Biopharma's NXC-201 Trial Meets Primary Endpoint in AL Amyloidosis
Jun 3, 2025
03:30 PM EDT, 06/03/2025 (MT Newswires) -- Immix Biopharma ( IMMX ) said the US multisite clinical trial evaluating its NXC-201 cell therapy in relapsed or refractory AL Amyloidosis achieved its primary endpoint of complete response. NXC-201 treatment resulted in a 70% complete response rate, and all of the patients in the trial had baseline relapsed or refractory AL Amyloidosis...
Copyright 2023-2026 - www.financetom.com All Rights Reserved